Trial · NCT04334460

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

NCT04334460, Phase 2, Completed, Blade Therapeutics; results first posted 2022-04-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. Trials, record NCT04334460. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04334460

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
NCT number: NCT04334460
Status: Completed
Phases: Phase 2
Enrollment: 120 participants, actual
Lead sponsor: Blade Therapeutics
Conditions: Sars-CoV-2, Covid19
Interventions: BLD-2660
First posted: 2020-04-06
Last updated: 2022-04-06
Results first posted: 2022-04-06

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time to Recovery	Course of study; 28 days	To evaluate time to recovery as defined by no longer requiring oxygen support or hospital discharge, whichever occurs first.
Primary	Change in Oxygenation	10 days	To evaluate change in oxygenation in hospitalized adults with COVID-19 treated with BLD-2660. Measured by change from baseline to Day 10 or hospital discharge, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen (SpO2/FiO2)
Secondary	Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Course of study; 28 days	To evaluate the safety and tolerability of BLD-2660 in the same population. Measured by incidence of TEAEs and serious adverse events (SAEs)
Other	Time to Discharge Readiness	Course of study; 28 days	Measured by time to discharge readiness
Other	Proportion of Subjects Discharged During Study	Course of study; 28 days	Measured by proportion of subjects ready to be discharged from the hospital during the 28-day study period following enrollment.
Other	Time to Resolution of Fever	Course of study; 28 days	Measured by time to resolution of fever below entry criteria for 24 hours in subjects with fever at baseline
Other	Duration of Remdesivir Use	Course of study; 28 days	Measured by duration (in days) of remdesivir use in subjects starting remdesivir within 24 hours of first dose of BLD-2660
Other	Change in Clinical Status	Course of study; 28 days	Measured by change from baseline to Days 10, 14, 21 and 28 in clinical status outcome using a 6-point ordinal scale
Other	Percentage of Subjects in Each Category of the 6-point Ordinal Scale	Course of study; 28 days	Measured by percentage of subjects reporting each 6-point ordinal scale of the clinical status outcome assessment.
Other	Change in IL-6	Course of study; 28 days	Measured by change from baseline to Days 10, 14, 21 and 28 in IL-6 in ng/mL measured by analytical assay

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Time to Recovery	Course of study; 28 days	FAS Set	days	MEDIAN
PRIMARY	Change in Oxygenation	10 days	FAS Set	Ratio	LEAST_SQUARES_MEAN
SECONDARY	Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Course of study; 28 days	Safety Set	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Time to Discharge Readiness	Course of study; 28 days	FAS Set	Days	MEDIAN
OTHER_PRE_SPECIFIED	Proportion of Subjects Discharged During Study	Course of study; 28 days
OTHER_PRE_SPECIFIED	Time to Resolution of Fever	Course of study; 28 days
OTHER_PRE_SPECIFIED	Duration of Remdesivir Use	Course of study; 28 days
OTHER_PRE_SPECIFIED	Change in Clinical Status	Course of study; 28 days	FAS Set	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Percentage of Subjects in Each Category of the 6-point Ordinal Scale	Course of study; 28 days	FAS Set	Participants	COUNT_OF_PARTICIPANTS
OTHER_PRE_SPECIFIED	Change in IL-6	Course of study; 28 days	FAS Set. Only participants in the FAS with data at the respective time point are summarized.	ng/L	MEAN

1 to 10 of 11Source ClinicalTrials.gov

See all 11 outcomes

Results by group100

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Time to Recovery	Active Group		5	95% Confidence Interval 3.00 to 6.00	days
Time to Recovery	Placebo Group		4.5	95% Confidence Interval 4.00 to 6.00	days
Change in Oxygenation	Active Group		33.8	Standard Error 17.10	Ratio
Change in Oxygenation	Placebo Group		66.8	Standard Error 25.58	Ratio
Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Active Group	Number of Subjects with >=1 TEAE	42		Participants
Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Placebo Group	Number of Subjects with >=1 TEAE	23		Participants
Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Active Group	Number of Subjects with >=1 Treatment-Related TEAE	10		Participants
Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Placebo Group	Number of Subjects with >=1 Treatment-Related TEAE	6		Participants
Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Active Group	Number of Subjects with >=1 TEAE with Grade 3 or higher	12		Participants
Safety & Tolerability: Incidence of TEAEs and Serious Adverse Events (SAEs)	Placebo Group	Number of Subjects with >=1 TEAE with Grade 3 or higher	9		Participants

1 to 10 of 100Source ClinicalTrials.gov

See all 100 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Full Enrollment	STARTED	Active Group	81
Full Enrollment	STARTED	Placebo Group	39
Full Enrollment	COMPLETED	Active Group	81
Full Enrollment	COMPLETED	Placebo Group	39
Full Enrollment	NOT COMPLETED	Active Group	0
Full Enrollment	NOT COMPLETED	Placebo Group	0
Full Analysis Set (FAS)	STARTED	Active Group	81
Full Analysis Set (FAS)	STARTED	Placebo Group	39
Full Analysis Set (FAS)	COMPLETED	Active Group	77
Full Analysis Set (FAS)	COMPLETED	Placebo Group	38

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events188

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anaemia	Blood and lymphatic system disorders	Active Group	1	77
other	Anaemia	Blood and lymphatic system disorders	Placebo Group	0	38
other	Leukocytosis	Blood and lymphatic system disorders	Active Group	1	77
other	Leukocytosis	Blood and lymphatic system disorders	Placebo Group	0	38
other	Leukopenia	Blood and lymphatic system disorders	Active Group	1	77
other	Leukopenia	Blood and lymphatic system disorders	Placebo Group	0	38
other	Angina pectoris	Cardiac disorders	Active Group	1	77
other	Angina pectoris	Cardiac disorders	Placebo Group	0	38
other	Cardiomegaly	Cardiac disorders	Active Group	0	77
other	Cardiomegaly	Cardiac disorders	Placebo Group	1	38

1 to 10 of 188Source ClinicalTrials.gov

See all 188 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Active Group	2	77
Total, all-cause mortality	Placebo Group	2	38
Total, other adverse events	Active Group	42	77
Total, other adverse events	Placebo Group	23	38
Total, serious adverse events	Active Group	9	77
Total, serious adverse events	Placebo Group	9	38

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Active Group vs Placebo Group: deaths from any cause	Trial comparisons
Active Group vs Placebo Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04334460

GET https://conductscience.org/api/trials/v1/NCT04334460/results?page=2

API reference For AI assistants